By Melissa Busch, assistant editor

November 4, 2019 -- Radiation oncologist Dr. Stephen Hahn has been nominated as commissioner of the U.S. Food and Drug Administration (FDA). The nomination is drawing plaudits from the American Society for Radiation Oncology (ASTRO) and other cancer organizations.

Dr. Stephen Hahn
Dr. Stephen Hahn.

Currently the chief medical executive of MD Anderson Cancer Center, Hahn served on ASTRO's board of directors from 2014 to 2018. Hahn also previously obtained the rank of commander in the U.S. Public Health Service.

ASTRO noted Hahn's clinical expertise and training in internal medicine, medical oncology, and radiation oncology, as well as his international recognition in treating lung cancer, which the society said makes him ready to tackle some of the toughest issues facing the FDA. Additionally, he is well-versed on the drug, biologic, and device development pipeline, which has been demonstrated in his role in developing multiple medical products.

ASTRO urged the U.S. Senate to swiftly confirm Hahn's nomination, which President Trump announced on November 1. The American Association for Cancer Research (AACR) also congratulated Hahn, noting that he has been a member of the group since 1999 and has served on a number of AACR committees and research groups over the years.

In related news, acting FDA Commissioner Dr. Ned Sharpless will return to his role as director of the U.S. National Cancer Institute. Sharpless ran the FDA for seven months following the departure of Dr. Scott Gottlieb.

FDA airs 'to do' list for devices in 2020
The U.S. Food and Drug Administration's (FDA) priorities for new guidance documents on medical devices in fiscal 2020 include updated recommendations...
FDA seeks patient engagement in device design, development
The U.S. Food and Drug Administration (FDA) has published draft guidance on how device manufacturers should engage patients when designing medical devices.
ACLA blasts FDA's 'troubling actions' on pharmacogenetic tests
The American Clinical Laboratory Association (ACLA) has requested a meeting with officials at the U.S. Food and Drug Administration (FDA) regarding the...
FDA announces draft guidance on pathology peer review
The U.S. Food and Drug Administration (FDA) recently released draft recommendations to better guide nonclinical laboratory staff and sponsors conducting...
FDA brings glucose meter problems out into the open
The U.S. Food and Drug Administration's (FDA) just-released data from its now defunct Alternative Summary Reporting program shed light on millions...

Copyright © 2019

Last Updated np 11/4/2019 12:57:31 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.